Pinky Ronen
Gynecology · Houston, TXNPI 1821098112
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,182 and has fallen 67.5% since, to $384 in 2025.
Across 157 payments — averaging $22.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$456
- AbbVie$302
- Davol Inc.$233
- Shield Therapeutics Inc$232
- Millicent US Inc$209
- Therapeuticsmd, Inc.$202
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,47098%
- Education$612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 26 | $456 |
| AbbVie(2 entities) | 15 | $302 |
| Davol Inc. | 2 | $233 |
| Shield Therapeutics Inc | 13 | $232 |
| Millicent US Inc | 12 | $209 |
| Therapeuticsmd, Inc. | 13 | $202 |
| Biogen | 8 | $200 |
| Radius Health, Inc. | 4 | $161 |
| Olympus America Inc. | 1 | $148 |
| Astellas Pharma US Inc | 7 | $146 |
| Exeltis, USA Inc. | 7 | $146 |
| BD | 1 | $134 |
| Sumitomo Pharma America, Inc. | 6 | $112 |
| Hologic Sales And Service, LLC | 5 | $96 |
| Mayne Pharma Commercial LLC | 4 | $86 |
| Intuitive Surgical | 1 | $77 |
| Lupin Inc. | 3 | $53 |
| Avion Pharmaceuticals | 3 | $52 |
| Mimedx Group, Inc. | 2 | $42 |
| Agile Therapeutics, Inc. | 2 | $37 |
| Innovation Technologies Inc | 1 | $35 |
| AMAG Pharmaceuticals, Inc. | 2 | $34 |
| Amgen | 2 | $33 |
| Johnson & Johnson | 1 | $24 |
| Scynexis, Inc. | 1 | $24 |
| Mylan Pharmaceuticals Inc. | 1 | $23 |
| Roche Diagnostics Corporation | 1 | $23 |
| Organon | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $21 |
| Mission Pharmacal Company | 1 | $21 |
| Covidien LP | 1 | $20 |
| Dysis Medical, Inc. | 2 | $19 |
| Evofem Biosciences, Inc. | 1 | $18 |
| Duchesnay USA Incorporated | 1 | $18 |
| Aspira Women's Health Inc | 1 | $18 |
| Acessa Health Inc. | 1 | $16 |
| Exact Sciences | 1 | $14 |
| Coopersurgical, Inc. | 1 | $14 |
| Minerva Surgical, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Olympus Surgical Accessories$148
- PHASIX$134
- ALLOMAX$134
- Tymlos$123
How this compares
$3,531 in reported general payments places this provider in the 80th percentile of 161 gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 43 | $2,335 |
| Ibandronate Sodium | 21 | $505 |
| ValacyclovirValacyclovir Hcl | 20 | $382 |
| SynthroidLevothyroxine Sodium | 12 | $354 |
| Levothyroxine Sodium | 26 | $253 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $143 |
| Rosuvastatin Calcium | 13 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSynthroid | $302 | $35412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 161 gynecology providers in Texas.
Other gynecology in Houston
- Robert ZurawinHouston$61K
- Nicolas XydasHouston$19K
- Maurice LeibmanHouston$10K
- Glenn MorganHouston$7K
- Alfred PoindexterHouston$5K
- M Bruce ChristophersonHouston$3K
- John IrwinHouston$2K
- Richard FarnamEl Paso$1.2M
- Jessica ShepherdDallas$809K
- Linda LacyEl Paso$627K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.